Abstract
The potential for a pharmacokinetic interaction between epirubicin and the second-generation multidrug resistance modulating agent D-verapamil (DVPM) has been investigated in six patients with advanced colorectal cancer. Our results indicate that a significant interaction takes place. Enhanced distribution of epirubicin from the serum and altered disposition might, in fact, explain the increased level of myelotoxicity in this pilot as well as in other clinical phase II studies involving DVPM.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scheithauer, W., Schenk, T. & Czejka, M. Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil. Br J Cancer 68, 8–9 (1993). https://doi.org/10.1038/bjc.1993.277
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.277
This article is cited by
-
Inhibitory effect of calcium channel blockers on human mesangial cell growth: Evidence for actions independent of L-type Ca2+ channels
Kidney International (1996)
-
In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation
Cancer Chemotherapy and Pharmacology (1995)
-
Dexverapamil to overcome epirubicin resistance in advanced breast cancer
Journal of Cancer Research and Clinical Oncology (1995)
-
Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma
Journal of Cancer Research and Clinical Oncology (1995)
